AWhat changed
A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality.
Scientific scope
A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality. Scope limitation: The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.
Evidence
Assessment uses the catalogue-linked source evidence for the stated contribution. The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.
Contributors
- The research collaboration listed in the linked record and source byline · SCIENCE: Collective scoped contribution. The complete recorded byline remains in the research record; this label does not collapse people into one individual.
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia — deposited bibliography
- Druker and colleagues: original phase 1 trial abstract
Provisional WRS assessment, edition 2026-10-16.1. Independent expert calibration is pending. This grade does not certify correctness or assign ownership.
Full scientific record · Browse contribution grades · Request a correction